Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

R1000600

Risperidone

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

R 64,766

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C23H27FN4O2
Número de CAS:
106266-06-2
Peso molecular:
410.48
Número MDL:
MFCD00274576
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329823994
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

risperidone

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

Clave InChI

RAPZEAPATHNIPO-UHFFFAOYSA-N

Información sobre el gen

human ... DRD2(1813) , HTR2A(3356) , HTR2C(3358)

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Risperidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

1604665

Risperidone System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1604654

Risperidone, United States Pharmacopeia (USP) Reference Standard

Y0000370

Risperidone for system suitability, European Pharmacopoeia (EP) Reference Standard

1604676

Risperidone Related Compounds Mixture, United States Pharmacopeia (USP) Reference Standard

Y0001276

Risperidone impurity K, European Pharmacopoeia (EP) Reference Standard

1604756

Risperidone Related Compound G, United States Pharmacopeia (USP) Reference Standard

BP1137

Risperidone, British Pharmacopoeia (BP) Reference Standard

BP1158

Risperidone impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogramas

Skull and crossbones
GHS06

Palabra de señalización

Danger

Frases de peligro

H301

Clasificaciones de peligro

Acute Tox. 3 Oral

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
Andrea Fagiolini et al.
Expert opinion on pharmacotherapy, 11(10), 1727-1740 (2010-05-22)
It is very rare for patients with bipolar disorder to have a single episode of mania or depression over a lifetime and the vast majority of these individuals need long-term prophylactic/maintenance treatment. However, treatment nonadherence is a major issue for
W Victor R Vieweg et al.
Psychopharmacology, 228(4), 515-524 (2013-07-03)
A recent publication asserted that even low-dose risperidone may induce corrected QT (QTc) interval prolongation up to 500 ms without drug-induced IKr blockade. We seek to better understand the complexity of any link between risperidone-induced/associated QTc interval prolongation and torsade de
Jérôme A J Becker et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)
The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))
Christian Spang Pedersen et al.
Behavioural brain research, 273, 63-72 (2014-07-30)
Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico